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Op 18 is a highly conserved major cytosolic phosphoprotein which has been implicated in 
signal transduction in a wide variety of cell types. Freshly isolated peripheral blood lymphocytes 
(PBL) constitutively express low levels of mostly unphosphorylated Op18. Following mitogenic 
stimulation of PBL, Op 18 synthesis is induced at a time when cells are entering S-phase. In this 
study we have characterized Op18 phosphorylation during progression of freshly isolated PBL 
through the cell cycle. Transition from GO to G1 following activation with OKT3 was associated 
with an increase in a phosphorylated form designated Op 18c. Progression of cells through G 1 into 
S resulted in an increase in phosphorylated Opl 8 forms, designated Opl8a and Op 18b, which 
paralleled new Op18 synthesis. Transition of cells into G2+M resulted in the appearance of the 
more acidic phosphorylated forms Opl8d and Opl8e. Calphostin C, a specific inhibitor of protein 
kinase C, dramatically decreased all forms of phosphorylated Op18 in OKT3 treated Jurkat cells. 
Our results suggest that Op18 phosphorylation is mediated in part by PKC activation as well as by 
other ldnases yielding different phosphorylated forms at specific stages of the cell cycle. ~ ~992 
Academic Press, Inc. 
Op18 is a proliferation related protein which in PBL is induced in late G1 following 
mitogenic stimulation (1-3) and which is overexpressed in acute leukemia and some solid tumors 
(1). We have cloned and sequenced two cDNAs for Op18 which code for the same 149 amino 
acid polypeptide (4). Disruption of Op18 mRNA translation with antisense oligonucleotides 
resulted in delayed entrance of PBL into S phase (5). Conversely, induction to terminal 
differentiation of K562 erythroleukemia cell line with hemin (5) and of HL-60 promyelocytic 
leukemia cell line with DMSO or PMA (2) resulted in down-regulation of Op18 levels. 
Comparison of the human cDNA coding sequence for Op18 with sequences published to 
date has revealed that Op 18 is identical to a cytosolic polypeptide observed in different species and 
designated by by others as stathmin (6), p19 (7) and 19K (8) and that Op18 exhibits a high degree 
of conservation in its amino acid sequence. Also, from its pI and MW on 2-D gels, Op 18 is highly 
likely identical to prosolin (3) and pp21/pp23 (9) described in proliferating PBL and T cell lines. 
Op18 undergoes phosphorylation in a wide variety of proliferating cells (10). Its 
phosphorylation has been implicated in signal transduction in rat brain (11) and PC12 cells (6). In 
quiescent PBL, Op18 is present at low levels. However two phosphorylated forms can be detected 
by metabolic labeling with 32p i (12). Additional phosphorylated forms have been observed in 
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proliferating T cells by ourselves (12) and others (3, 13, 14) following mitogenic stimulation. We 
have identified as many as seven phosphorylated forms of Op18 in PMA activated Jurkat cells by 
Western blotting (12). Two phosphorylated forms with an apparent mass of 17.3 kD designated 
Opl8a and b have pI 5.80 and 5.61, respectively, compared to pI 6.0 of unphosphorylated 17.3 
kD Op18. Opl8c is an 18.1 kD form with pI similar to Opl8b. Opl8d is more acidic (pI 5.42) 
and has greater apparent mass (18.8 kD). Three minor 17.3 kD forms have pls 5.66, 5.48 and 
5.40. We have recently described protein kinase C mediated phosphorylation of Op18 giving rise 
to the form designated Opl8c as early as 2 min following T cell activation (12). 
In this study we have characterized Op18 phosphorylation in freshly isolated PBL during 
cell cycle progression. Our results indicate a different pattern of phosphorylation related changes 
in Op18, at differnt stages of the cell cycle. 
METHODS 
Peripheral blood lymphocyte preparation and cell synchronization: Human PBL 
were prepared from venous blood of healthy volunteers. Whole mononuclear cells were isolated 
from heparanized blood by centrifugation (1500 x g, 15 rain, room temperature) over Ficoll-Paque 
(Pharmacia) and cultured in RPMI 1640 supplemented with 10% fetal calf serum. PBL were 
mitogenically stimulated with anti-CD3 (OKT3 ascites, 1:200). To achieve synchronization, 10 
mM hydroxyurea was added 24 h following OKT3 stimulation and PBL were cultured for an 
additional 20 h to allow cells to accumulate in S phase. Cells were washed three times with media 
and returned to the original flask with fresh OKT3 added. Three h following release of the block 
in S phase, 100 ng/ml nocodazole was added for 21 h to block cells in M. The leukemia T cell line 
Jurkat was maintained in supplemented RPMI 1640 at a density of 0.5-1 x 106/mi. 
Cell cycle analysis: The percentage of cells in G0/G1, S and G2+M was determined by DNA 
staining with propidium iodide (15). Cells were fixed in 70% ethanol and incubated overnight at 
4 ° C. Cells were resuspended in MEM containing 2% newborn calf serum, 500 U/ml RNase A 
and 0.1% sodium azide and incubated at 37 ° C for 1 h. An equal volume of 50 ~tg/ml propidium 
iodide in 1.12% sodium citrate, pH 8.4 was added and cells were incubated at room temperature 
for 30 rain. The samples were analyzed on a FACScan (Becton Dickinson). DNA content was 
determined by rectangular modeling using the CellFIT software program. 
[32p] incorporation: Non-adherent cells (2.5 x 106 cells) were washed once with phosphate- 
free RPMI 1640 and resuspended in 300 ktl phosphate-free medium containing [32p]_ 
orthophosphate (450 ~tCi/ml, carder free; Amersham), in 1.5 ml microcentfifuge tubes. Incubation 
at 37 ° C was for 60 to 90 min. For inhibition studies using the specific protein kinase C (PKC) 
inhibitor calphostin C (Kamiya Biochemical) the working stock solution was activated by exposure 
to fluorescent light for 15 min prior to addition to cells (16). 
Two dimensional polyacrylamide gel electrophoresis (2-D PAGE): Two-dimensional 
PAGE using carrier ampholyte-based isoelectric focusing was performed as previously described 
(17) using pH 4-8 Resolyte (2% w/v; Hoefer Scientific). Whole cell lysates were prepared (2.5 x 
106 cells) with 30 p.1 lysis solution (9.5 M urea, 2% 2-mercaptoethanol, 2% Nonidet-P40, 
containing 50 mM NaF and 0.1 mM Na vanadate as phosphatase inhibitors). The lysate was 
centrifuged for 2 rain and 2.5 x 106 cell equivalents were applied to the isofocusing gel. Focusing 
was for 16 h at 1000 V. The second dimension separation was an 11.4 to 15% acrylamide 
gradient SDS gel. Following the second dimension separation, proteins were fixed in the gel with 
50% ethanol and 5% acetic acid. Gels were washed for 15 min with 2% glycerol and 30% ethanol 
and dried. Phosphorylated polypeptide 2-D images were obtained using a PhosphorImager 
System (Molecular Dynamics) (18). Exposure time was 41 to 72 h. 
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RESULTS 
Cell cycle analysis of PBL: To determine whether Op18 phosphorylation is modulated 
during transition of ceils through the cell cycle, PBL were synchronized with a combination of 
hydroxyurea and nocodazole. PBL were stimulated through the T cell receptor with anti-CD3 
(OKT3) for 24 h and subsequently treated with hydroxyurea, which inhibits ribonucleoside 
diphosphate reductase, and nocodazole, a microtubule-depolymerizing drug, to modulate transit 
through the cell cycle. The DNA content histogram is shown in Figure 1. DNA content of cells 
was determined by FACS analysis. By 47 h, 24% of the cells entered the cell cycle (S+G2+M). 
Following 24 h of OKT3 treatment the majority of PBL (92%) remained in G0/G1. Hydroxyurea 
was added and the incubation continued for 20 h to allow cells to accumulate in S phase. Less than 
2% of cells escaped into G2+M phase. Following release of the hydroxyurea block there was a 
further increase in the proportion of cells in S phase. Subsequent treatment three h later with 
nocodazole resulted in arrest of cells in M phase. During the 21 h of treatment with nocodazole the 
proportion of S phase cells declined while an equivalent proportion of cells accumulated in G2+M. 
Phosphorylation of Op18 in relation to the cell cycle: To relate Op18 phosphorylation 
to transition of PBL through the cell cycle, PBL at different stages of the cell cycle shown in 
Figure 1, were labeled with 32p i in the presence of the appropriate pharmacologic agent and 
phosphorylated Op18 was analyzed by 2-D gel electrophoresis. Freshly isolated quiescent (GO) 
PBL express low levels of Op18, however two phosphorylated forms, OplSa and OplSb, can be 
detected on 2-D gels of cells metabolically labeled with 32p i using storage phosphor imaging (Fig. 
2A). Within 5 min of stimulation of the TCR with OKT3, another form, Op18c, is prominently 
expressed and Opl8a and Opl8b are slightly increased (Fig. 2B). The 24 h OKT3 treated cells did 
not express Op18c and the amount of Opl8a and Opl8b increased slightly compared to the levels 
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F_~gure 1. Cell cycle analysis of PBL by propidium iodide staining of DNA. The proportion of 
cells in various stages of the cell cycle was manipulated by sequential treatment of PBL with 10 
mM hydroxyurea (HU) and 100 ng/ml nocodazole (NOC) for the indicated times. DNA content of 
cells was determined by propidium iodide staining and FACS analysis. 
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Figure 2, 2-D gel analysis of phosphorylated Op18 during the cell cycle. Freshly isolated PBL in 
GO were labeled with 32p i for 60 min and Op18 phosphorylated forms were analyzed by 2-D 
electrophoresis (Panel A). To obtain cells in the GO to G1 Ixansition, PBL were labeled as in panel 
A except that OKT3 was added during the last 5 min. (Panel B). PBL arrested in S phase (44 h of 
Fig. 1) were labeled in the presence of hydroxyurea (Panel C). PBL arrested in M phase (68 h of 
Fig.I) were labeled in the presence of nocodazole (Panel D). Phosphor storage screen exposure 
time in panels A and B is increased to permit clear visualization of Opl8a and Opl8b. 
seen in Fig. 2B (data not shown). Analysis of PBL in S phase following 20 h of hydroxyurea 
treatment revealed a substantial increase in the amount of Opl8a and Opl8b whereas Opl8c was 
still undetectable (Fig. 2C). Three h following removal of hydroxyurea, cells continued to enter S 
phase, however there was no significant change in Op18 phosphorylation (data not shown). 
Nocodazole was then added to the medium and the incubation continued. A significant number of 
cells entered G2+M by 21 h of nocodazole treatment (Fig. 1). At this time cells expressed 
phosphorylated Opl8d and another phosphorylated polypeptide identified as Opl8e (Fig. 2D), on 
the basis of Western blotting of PMA-activated Jurkat cells using anti-Op 18. Again, Op 18c could 
not be detected in cells arrested in M phase. 
Inhibition of Op18 phosphorylation by calphostin C: In a previous study, we observed 
that the early phosphorylation producing Opl8a, Opl8b and Op18c in OKT3 stimulated PBL was 
inhibited by calphostin C, a specific inhibitor of protein kinase C, but not by HA1004, an inhibitor 
of cyclic nucleotide-dependent protein kinases (12). To determine the involvement of protein 
kinase C in Opl8d and Opl8e phosphorylation we examined phosphorylation patterns in Jurkat 
cells. Jurkat cells treated with OKT3 express all five of these phosphorylated forms of Op 18 (Fig. 
3A). When Jurkat cells were treated with calphostin C (1.26 ~tM) during the prelabeling period 
and were subsequently treated with OKT3 for 15 rain there was a dramatic decrease in the extent of 
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Fa_~gure 3. Inhibition of Op18 phosphorylation in Jurkat cells by calphostin C. Jurkat cells were 
labeled for 90 min with 32p i without (Panel A) or with 1.26 ~tM calphostin C (Panel B). OKT3 
was added during the last 15 min. 
Op 18 phosphorylation (Fig. 3B). Phosphorylation of  Op 18c, Op 18d and Op 18e were virtually 
eliminated while levels of  Opl8a and Opl8b were substantially reduced. Interestingly calphostin C 
treatment resulted in the appearance of  a series of  minor, more acidic phosphoproteins of similar 
MW as Opl8a  and Opl8b. It is not known whether these phosphoproteins are related to Op18. 
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D I S C U S S I O N  
The studies presented demonstrate changes in the pattern of phosphorylation of Op 18 
during cell cycle progression. Whereas Opl8a and Opl8b were expressed throughout the cell 
cycle, Opl8c was expressed only in early G1 and Opl8d and Opl8e were expressed in M phase. 
In asynchronous PBL activated with OKT3 we have observed the gradual loss of Op18c by 24 to 
48 h following stimulation. Expression of Opl8c is not seen again until 48 to 72 h later (data not 
shown). In cell cycle experiments presented in this report we have not observed Opl 8c in late G1, 
S, G2 and M phases. The reappearance of Opl8c in asynchronous cells therefore likely reflects 
phosphorylation in cells that have completed the cell cycle and are in early G1, the stage during 
which Opl8c was observed during transition from GO. 
Phosphorylated forms OplSd and Opl8e were observed in M phase-arrested PBL. Their 
appearance followed induction of new Op18 synthesis in late G1/S. By 3 h following release of 
the M phase block Opl8d and Opl8e levels decreased nearly 10 fold (data not shown). Op18 and 
its phosphorylated forms are found in the cytosol and are not found in isolated nuclei. Our results 
suggest that Op 18d and Op 18e phosphorylation most likely occurs in M following completion of 
DNA synthesis when the nuclear membrane is absent. Specific nuclear protein kinases and 
phosphatases induced during G2 and M phases may be accessable to the cytoplasmic compartment 
and be capable of phosphorylating Op18 or regulating cytoplasmic protein ldnases responsible for 
Op18 phosphorylation. The results suggest that Opl8d and Opl8e may be involved in mitotic 
events prior to chromosomal segregation and cell division. 
Prior studies of Op18 phosphorylation in human T cells have utilized asynchronous rapidly 
proliferating cells (2, 9-11, 13). Two phosphorylated polypeptides corresponding to Opl8c and 
Opl 8d were found to be rapidly phosphorylated in response to TCR-CD3 activation in Jurkat cells, 
(9, 13) IL-2 dependent PBL cultures (19) and a normal CD4 + T cell line P28D (20). The 
expression of Opl8c and Opl8d in P28D cells was variable depending on the signal transduction 
pathway which was activated (20). Expression of Op18c may reflect that proportion of cells in 
early G1. The basis for the differential effect on rapid phosphorylation of Opl8d in T cell lines 
and IL-2 dependent T cell cultures compared to freshly isolated synchronized T cells may be related 
to levels of different precursor phosphorylated forms or to their cytoplasmic compartmentalization, 
or to the state of activation of other signaling molecules or pathways. 
Inhibition studies of protein kinase C with calphostin C suggest involvement of this kinase 
in Op18 phosphorylation. However the findings do not necessarily indicate that Op18 is a 
substrate for protein kinase C. Numerous kinases and phosphatases are induced as part of the T 
cell activation cascade whose activities may be regulated in part by protein kinase C. The 
occurrence of phosphorylated forms of Op18 that differ in isoelectfic points is likely the result of 
phosphorylation at a variable number of sites. The more acidic forms presumably are 
phosphorylated at a greater number of residues. However other post-translational modifications 
resulting in increased net negative charge may also be partially responsible for Op18 heterogeneity. 
Identification of Op18 phosphorylation sites in the different phosphorylation forms will 
substantially contribute to elucidation of precursor/product relationships in Opl 8 phosphorylation 
and their potential role in cell proliferation. 
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